Under the collaboration Evonik and Elevance are also expected to further develop the application of metathesis catalysts within Elevance’s business scope.
Elevance manufactures oils, lubricants additives, antimicrobials and other chemicals from such bio-renewables, and competes with petrochemical based products.
K’Lynne Johnson, CEO of Elevance, said: “Metathesis reactions are a key step in our bio refinery process to make the conversion from natural oils to specialty chemicals. Evonik’s licensed metathesis catalysts complement our existing catalyst portfolio.”
Wilfried Eul, senior vice president and head of catalyst business at Evonik, said: “We are looking forward to Elevance’s application of metathesis reactions in the conversion of natural oils.”
Martin Bankmann, head of strategic projects in catalysts business line of Evonik, said: “In accordance with Evonik’s business model the price for patented metathesis catalysts from the catMETium RF portfolio already includes the licensing fees for the use of Evonik’s intellectual property rights.”